Recent briefings covering the 30-day period through mid-September 2026 recorded no material discrete corporate events, new regulatory disclosures, or new corporate announcements for AbbVie Inc. Successive briefs dated through 2026-09-11 each noted the absence of new filings beyond routine administrative activity during the period [Brief - 2026-09-11].
As of the quarter ending 30 June 2026, AbbVie reported trailing twelve-month revenue of $64.39 billion, representing year-over-year growth of 10.16%. Net income on a TTM basis stood at $6.31 billion, yielding a net margin of 9.80%. Gross margin was recorded at 65.73% and operating margin at 26.20%. EPS grew 290.38% year-over-year on a TTM basis, and the trailing P/E ratio was 74.56. Cash on hand was $6.57 billion against total debt of $64.50 billion [SEC 10-Q - ABBV - 2026-06-30].
Institutional ownership data reflects material position changes across several large filers. Citadel added 76% to its ABBV position, Millennium added 35%, and AQR Capital added 127% to its position. Conversely, Bridgewater reduced its ABBV position by 61% [SEC 13F - Citadel - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026]. No insider transaction data was available for the current reporting period.
The prevailing macro environment reflects a 10-year US Treasury yield of 4.94% and a 2-year yield of 4.67%, producing a normal yield curve with a spread of approximately 27 basis points [FRED DGS10] [FRED DGS2]. This rate environment forms the broader context within which AbbVie's debt load of $64.50 billion and financing costs are assessed by market participants.
This report was generated in response to material institutional position changes identified across multiple 13F filers during the most recent quarterly disclosure cycle, representing the primary triggering event for this publication.